IRIS
ALTAVILLA, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.967
NA - Nord America 10.125
AS - Asia 5.077
SA - Sud America 1.719
Continente sconosciuto - Info sul continente non disponibili 294
AF - Africa 136
OC - Oceania 12
Totale 28.330
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.943
RU - Federazione Russa 5.153
SG - Singapore 2.192
BR - Brasile 1.511
CN - Cina 1.464
IE - Irlanda 1.302
SE - Svezia 1.241
IT - Italia 880
HK - Hong Kong 539
DE - Germania 504
UA - Ucraina 482
GB - Regno Unito 328
FR - Francia 317
FI - Finlandia 265
VN - Vietnam 249
PL - Polonia 195
IN - India 142
BD - Bangladesh 100
CA - Canada 72
BE - Belgio 65
TR - Turchia 61
AR - Argentina 54
MX - Messico 54
IQ - Iraq 47
EC - Ecuador 43
ZA - Sudafrica 41
CO - Colombia 38
ES - Italia 37
ID - Indonesia 36
NL - Olanda 36
AT - Austria 32
UZ - Uzbekistan 28
CZ - Repubblica Ceca 24
JP - Giappone 24
MA - Marocco 24
VE - Venezuela 24
AE - Emirati Arabi Uniti 17
PK - Pakistan 17
IR - Iran 15
SA - Arabia Saudita 15
AZ - Azerbaigian 14
AL - Albania 13
BO - Bolivia 13
JM - Giamaica 13
KE - Kenya 12
CL - Cile 11
LT - Lituania 11
TN - Tunisia 11
CH - Svizzera 10
CI - Costa d'Avorio 10
JO - Giordania 10
NP - Nepal 10
PH - Filippine 10
PY - Paraguay 10
AU - Australia 9
EG - Egitto 9
IL - Israele 9
KG - Kirghizistan 9
DO - Repubblica Dominicana 8
GR - Grecia 8
KZ - Kazakistan 8
OM - Oman 8
PS - Palestinian Territory 8
RS - Serbia 8
NO - Norvegia 7
PE - Perù 7
CR - Costa Rica 6
NI - Nicaragua 6
RO - Romania 6
TH - Thailandia 6
UY - Uruguay 6
AM - Armenia 5
AO - Angola 5
BA - Bosnia-Erzegovina 5
BG - Bulgaria 5
GE - Georgia 5
LB - Libano 5
PA - Panama 5
SV - El Salvador 5
BY - Bielorussia 4
DZ - Algeria 4
ET - Etiopia 4
HN - Honduras 4
KR - Corea 4
KW - Kuwait 4
LV - Lettonia 4
MY - Malesia 4
PT - Portogallo 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
TT - Trinidad e Tobago 4
DK - Danimarca 3
GT - Guatemala 3
HR - Croazia 3
HU - Ungheria 3
NZ - Nuova Zelanda 3
XK - ???statistics.table.value.countryCode.XK??? 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BW - Botswana 2
EE - Estonia 2
Totale 28.009
Salva come PNG Salva come JPEG
Città #
Moscow 1.476
Ashburn 1.361
Dublin 1.302
Singapore 1.174
Chandler 990
Jacksonville 943
Dallas 916
Nyköping 691
San Jose 541
Hong Kong 534
Beijing 492
Council Bluffs 328
The Dalles 295
Dearborn 251
Los Angeles 248
Ann Arbor 244
Princeton 218
Cambridge 199
Medford 199
Warsaw 188
Lauterbourg 183
New York 164
Messina 160
Des Moines 154
Boardman 130
Munich 121
São Paulo 118
Lancaster 110
Buffalo 89
Tianjin 82
Jinan 78
Ho Chi Minh City 75
Santa Clara 68
Woodbridge 67
Brussels 62
Orem 52
Shenyang 52
Guangzhou 51
Hanoi 51
Redondo Beach 51
Rio de Janeiro 51
Turku 50
Wilmington 48
San Mateo 45
Houston 44
Chicago 43
Frankfurt am Main 42
Columbus 39
Nanjing 37
Belo Horizonte 35
Milan 31
Atlanta 30
Catania 30
Rome 30
Brooklyn 29
Hyderabad 29
Montreal 29
Hebei 27
Seattle 27
Vienna 27
Brasília 26
Pune 26
San Francisco 26
Tashkent 26
Zhengzhou 26
London 24
Jakarta 23
Tokyo 23
Phoenix 22
Washington 22
Baghdad 21
Chennai 21
Denver 21
Curitiba 20
Haikou 20
Helsinki 20
Nanchang 20
Porto Alegre 20
Düsseldorf 19
Mumbai 19
Norwalk 19
Nuremberg 19
Shanghai 19
Stockholm 19
Istanbul 18
Johannesburg 18
Quito 18
Dong Ket 17
Ningbo 17
Salvador 17
Boston 16
Ankara 15
Bremen 15
Campinas 15
Hangzhou 15
Ribeirão Preto 15
Scarsdale 15
Shenzhen 15
Brno 14
Dhaka 14
Totale 16.006
Salva come PNG Salva come JPEG
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 429
Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome 244
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 237
Annual increase in the frequency of papillary thyroid carcinoma as diagnosed by fine-needle aspiration at a cytology unit in Sicily. 236
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 231
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 229
Mechanical dispersion and cardiotoxicity in patients who underwent chemotherapy for breast cancer: an echocardiographic study 229
Analysis of multilayer strain and myocardial work in patients undergoing chemotherapy treatment: a 12 months follow-up 228
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 227
Analisi dello stato di metilazione del promoter di O6-methylguanine DNA methyltransferase (MGMT) e TMS1/ASC nei gliomi cerebrali diffusi di basso grado: possibili implicazioni cliniche e prognostiche. 220
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 218
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 216
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) 213
Myocardial damage pattern in women with breast cancer who underwent chemotherapy: strain polar maps analysis 207
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 206
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 204
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 202
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data 201
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 199
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 195
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer 194
Increased annual frequency of Hashimoto's thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. 193
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer 193
Liquid biopsy for lung cancer early detection 193
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 192
[Serum levels of copper and zinc in patients with lung cancer] 192
Applications of genomics in NSCLC 189
Left atrial function in patients undergoing chemotherapy: additional value of 2D longitudinal strain 189
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 188
[(186)Re]HEDP in the palliation of painful bone metastases from cancers otherthan prostate and breast. 187
An acute-leukaemia-like picture due to breast carcinoma cells. 187
A randomized factorial trial of sequential doxrubicina and CMF vs CMF and chemoterapy alone vs chemoterapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer 187
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 186
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 185
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 184
Cancer screening in HIV-infected patients: early diagnosis in a high-risk population 184
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 183
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 180
Amplification and overexpression of the PSMB5 gene contribute to Bortezomib resistance in re-treatment of patients with Multiple Myeloma 179
Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer 178
A novel HPLC method for the determination of mitoxantrone in pharmaceutical formulations. 175
A PHASE III RANDOMIZED TRIAL COMPARING THREE PLATINUM-BASED DOUBLETS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): IMPACT OF PS=2 VS 0 OR 1 AND AGE ³70 VS <70 ON CHEMOTHERAPY OUTCOME 173
The treatment of peritoneal carcinomatosis in elderly patients. 173
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 172
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 172
Razionale e tecniche della chirurgia citoriduttiva e della chemioipertermia peritoneale. 171
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 169
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 169
Espressione differenziale di un panel di miRNA in tumori cerebrali astrogliali con diverso grado di malignità. 169
Analytical profile and release of lonidamine from pharmaceutical formulation 168
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 168
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 167
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. 167
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST 166
Unusual relapse of hepatocellular carcinoma 166
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 166
Psycho-Neuro-Endocrine-Immune System (PNEI) Involvement as Prognostic Marker in Breast Cancer Patients at 10 Years of Follow Up 165
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 163
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 162
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 159
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 158
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 157
Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy 156
Targeted drugs in small-cell lung cancer 156
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 156
Peritoneal carcinomatosis of colorectal origin. 155
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 155
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation 154
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 153
La farmacogenomica nei tumori del polmone 152
Gemcitabine combined with Oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma 152
Severe pulmonary complications after bortezomib treatment for multiple myeloma: An unrecognized pulmonary vasculitis? 151
Sternal metastasis as initial presentation of a unknown rectal cancer 150
First Line Chemotherapy with Oral Vinorelbine (oV) in Elderly Hormone-Refractory Prostate Cancer (HRPC) Patients (pts 149
Clodronate and radiotherapy for the treatment of osteolysis caused by metastasis of breast carcinoma and non-small cell lung carcinoma. A retrospective study 148
Thyroid function, autoimmunity and nodules in hematological malignancies 148
A PHASE II STUDY (21 day regimen) OF GEMCITABINE (Gem) AND CISPLATIN ( Cis) IN ADVANCED/METASTATIC TRANSITIONAL CELL CARCINOMA (TTC) OF BLADDER 147
Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur. 147
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 146
Transpersonal Therapy Combined with Best Supportive Care In Hospice Improve Patient’s Quality of Life and Quality Of Death 145
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. 145
SUBCUTANEOUS LOW-DOSE ALEMTUZUMAB AS FIRST LINE THERAPY FOR ELDERLY CLL PATIENTS WITH DELETION OF 17p 144
Extramedullary plasmacytoma presented as a non-functional invasive pituitary macro-adenoma. 144
Retrospective analiysis of P-STAT6 expression as predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 143
Salvage therapy for primary central nervous system lymphoma with Y-90-Ibritumomab and Temozolomide 143
Studio anatomo-clinico di due casi di sarcoma sinoviale monofasico del ginocchio 141
Use of bisphosphonates in oncology 140
Temozolomide-induced shrinkage of a pituitary carcinoma. 139
Beyond global longitudinal strain: early impairment of apical function after antracyclines therapy 137
How cells respond to interferons. 135
Serum levels of copper and zinc in patients with lung cancer 134
ERLOTINIB IN A PATIENT WITH ACUTE MYELOGENOUS LEUKEMIA AND CONCOMITANT NON-SMALL-CELL LUNG CANCER 134
Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: A surrogate marker of response? 134
Efficacy and toxicity of weekly Docetaxel as second/third line chemotherapy for advanced Non Small Cell lung cancer (NSCLC) 134
Behavior of serum sialic acid levels at various stages of neoplastic disease 133
DASATINIB INDUCES A RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA 133
MYELODYSPLASTIC SYNDROMES DEVELOPING DURING IMATINIB THERAPY FOR GIST 133
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). 133
Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer 127
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 126
Totale 17.441
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.838
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.838
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.538 0 224 45 40 58 20 84 60 31 244 269 463
2022/20233.895 309 370 174 284 303 396 57 235 1.601 22 95 49
2023/2024988 73 128 66 114 73 258 23 45 3 79 26 100
2024/20254.298 57 38 74 252 221 134 75 1.015 1.146 250 337 699
2025/202612.011 617 662 1.003 691 969 2.672 1.495 1.488 1.493 476 221 224
2026/2027678 218 460 0 0 0 0 0 0 0 0 0 0
Totale 28.330